Sacramento, California 95817


Purpose:

We have studied the potential of breast computed tomography (bCT) for breast imaging under an NIH-funded Biomedical Research Partnership (BRP) grant (R01 EB002138-10), and 4 breast CT scanners have been developed that have imaged over 600 women to date (under more than one IRB-approved protocol). The BRP grant cannot be renewed, and with this (resubmitted) R01 grant application, we seek to finalize our research in breast CT - The specific aims have been significantly modified as a result of the first critique, and we now focus on a narrower set of remaining issues. This version of the protocol will add breast magnetic resonance imaging (MRI) to the experimental procedures.


Study summary:

Clinical evaluation: Four hundred women who will be having breast biopsy as part of their standard care (BIRADS 4 and 5) will be recruited to undergo additional imaging prior to biopsy, including (research) pre-and post-contrast enhanced breast CT imaging of both breasts, as well as (standard, FDA approved) contrast enhanced breast MRI. The potential of non-contrast enhanced breast CT will be compared using receiver operating characteristic (ROC) methodology against mammography alone, as well as with mammography + tomosynthesis. The breast CT images (including both pre-and post-contrast images) will be compared using ROC methodology against standard-of-care contrast-enhanced MRI (which includes both non-contrast and contrast images). The results of the clinical trials proposed in this investigation should provide strong evidence in regards to the potential of breast CT for breast cancer screening in the normal risk and high risk populations.


Criteria:

Inclusion Criteria: - Age at least 35 years old - Diagnostic findings from prior mammography highly suggestive of breast malignancy (BI- RADS® category 4 or BI-RADS® category 5) - Not pregnant or breast-feeding - Ability to lie motionless for up to 5 minutes Exclusion Criteria: - Recent breast biopsy - History of moderate or severe reaction to contrast agent injection - History of Allergy to Iodine - History of multiple food and/or drug allergy - Currently taking Glucophage or Glucovance (Metformin) - History of Chronic Asthma - History of Diabetes Mellitus - Renal (kidney) disease, or solitary kidney - Recent lab tests showing elevated serum creatinine (≥ 1.5 mg/dL) - Recent lab tests showing estimated glomerular filtration rate (eGFR) ≤ 60 ml/minute - Positive urine pregnancy test or currently breast-feeding - Inability to understand the risks and benefits of the study - The standard MRI contraindications apply, including but not limited to: having a pacemaker or other implanted electronic device, metal foreign bodies within the eye, aneurysm clips, heart valve prosthesis, vascular stents, coils, intrauterine devices (IUDs), inferior vena cava (IVC) filters, gunshot wounds with retained bullet fragments.


NCT ID:

NCT00584233


Primary Contact:

Principal Investigator
John M. Boone, Ph.D.
UC Davis Dept. of Radiology


Backup Contact:

N/A


Location Contact:

Sacramento, California 95817
United States

John M. Boone, Ph.D.
Phone: 916-734-3158
Email: jmboone@ucdavis.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 17, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.